反应详情

(3aS,6aR)-3-(3-(4-(1H-1,2,4-triazol-3-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)hexahydro-2H-cyclopenta[d]oxazol-2-one (45 mg, 60%) as the TFA salt was made according to the method of Example 1, Step 4, substituting (3aS,6aR)-hexahydro-2H-cyclopenta[d]oxazol-2-one for (S)-4-isopropyloxazolidin-2-one and substituting 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole for 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole in Example 1, Step 8. LCMS (APCI+) m/z 388 [M+H]+.